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Abstract
A highly conserved signaling pathway involving insulin-like growth factor 1 (IGF1), and a cascade of intracellular
components that mediate its effects, plays a major role in the regulation of skeletal muscle growth. A central
component in this cascade is the kinase Akt, also called protein kinase B (PKB), which controls both protein
synthesis, via the kinases mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3b (GSK3b), and
protein degradation, via the transcription factors of the FoxO family. In this paper, we review the composition and
function of this pathway in skeletal muscle fibers, focusing on evidence obtained in vivo by transgenic and
knockout models and by muscle transient transfection experiments. Although this pathway is essential for muscle
growth during development and regeneration, its role in adult muscle response to mechanical load is less clear.
A full understanding of the operation of this pathway could help to design molecularly targeted therapeutics
aimed at preventing muscle wasting, which occurs in a variety of pathologic contexts and in the course of aging.
Introduction
Muscle wasting occurs in a variety of conditions, such as
cancer cachexia, diabetes, renal failure and heart failure,
and aging itself. The survival and quality of life of these
patients and of the older person can be improved by
counteracting loss of muscle mass and strength, and dif-
ferent approaches to this have been explored, including
nutritional supplementation, resistance training and ana-
bolic drugs. Recent advances in understanding the
mechanisms responsible for muscle atrophy may pave
the way to new and perhaps more effective treatments.
During the past several years, experimental studies
based on rigorous genetic approaches have started to
dissect the signaling pathways involved in muscle-mass
regulation. Although studies on cultured muscle cells
have contributed to identify these pathways, definitive
evidence of their physiological relevance can only be
obtained using in vivo systems, when myofibers have a
mature structure, and the integrity of the neuromuscular
and musculoskeletal system is preserved.
Two in vivo g e n e t i ca p p r o a c h e sh a v eb e e nu s e dt o
understand how muscle mass is regulated. One is based
on the generation of transgenic and knockout mice, in
which expression of muscle regulatory genes is selec-
tively modified. The potential of the traditional gene
overexpression or deletion approaches has been fully
exploited with the introduction of the Cre/loxP techni-
q u ea n dt h eu s eo fi n d u c i b l et r a n s g e n e s ,w h i c ha l l o w s
for the modulation of gene expression specifically in
muscle tissues and at different developmental stages. It
is thus possible to distinguish between the effects on the
regulation of muscle growth during development from
the effects on the maintenance of muscle mass in adult-
hood. An alternative approach to address muscle-mass
regulation in the adult is based on in vivo transfection
of skeletal muscles by electroporation with plasmids
coding for specific components of signaling pathways, or
for mutants bearing constitutively active or dominant
negative properties. Transfection with plasmids able to
generate specific small interfering RNAs in muscle fibers
is also increasingly being used as a loss-of-function
model. The ability of various factors in preventing mus-
cle atrophy can be explored by transfecting denervated
muscles. * Correspondence: stefano.schiaffino@unipd.it
1Venetian Institute of Molecular Medicine (VIMM), Padova, Italy
Full list of author information is available at the end of the article
Schiaffino and Mammucari Skeletal Muscle 2011, 1:4
http://www.skeletalmusclejournal.com/content/1/1/4 Skeletal Muscle
© 2011 Schiaffino and Mammucari; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.In this review, we discuss how in vivo studies based on
these genetic models have contributed to define the role
of a specific signaling pathway, the insulin-like growth
factor 1-Akt/protein kinase B (IGF1-Akt/PKB) pathway,
in muscle mass regulation. Various aspects of the role of
this pathway in skeletal muscle have been previously
discussed [1-3]. The IGF1-Akt1 pathway shares most of
its components with the insulin-Akt2 pathway, and the
two pathways intersect at various levels. For example,
insulin can also bind the IGF1 receptor and IGF1 can
bind to the insulin receptor; furthermore, hybrids
between the IGF1 and insulin receptors are present in
skeletal muscle. However, insulin is especially important
in glucose homeostasis, whereas IGF1 is mostly active in
muscle growth. In this review, we consider exclusively
the role of this pathway on growth rather than on
metabolism.
Overview of the IGF1-Akt/PKB pathway
A simplified scheme of the IGF1-Akt pathway is shown
in Figure 1. Binding of IGF1 to its receptor leads to acti-
vation of its intrinsic tyrosine kinase and autophosphory-
lation, thus generating docking sites for insulin receptor
substrate (IRS), which is also phosphorylated by the IGF1
receptor. Phosphorylated IRS then acts as docking site to
recruit and activate phosphatidylinositol-3-kinase (PI3K)
which phosphorylates membrane phospholipids, generat-
ing phosphoinositide-3,4,5-triphosphate (PIP3) from
phosphoinositide-4,5-biphosphate (PIP2). PIP3 acts in
turn as a docking site for two kinases, phosphoinositide-
dependent kinase 1 (PDK1) and Akt, and the subsequent
phosphorylation of Akt at serine 308 by PDK1, leading to
Akt activation. All these steps take place at the inner sur-
face of the plasma membrane. Akt inhibits protein degra-
dation by phosphorylating and thus repressing the
transcription factors of the FoxO family, and stimulates
protein synthesis via the mammalian target of rapamycin
(mTOR) and glycogen synthase kinase 3b (GSK3b)[ 4 ] .
FoxO factors are required for the transcriptional regula-
tion of the ubiquitin ligases atrogin-1, also called muscle
atrophy F-box (MAFbx) and muscle ring finger 1
(MuRF1), leading to the ubiquitylation of myosin and
other muscle proteins (see below), and their degradation
via the proteasome. FoxO factors are also required for
the transcriptional regulation of the microtubule-asso-
ciated protein 1 light chain 3 (LC3), which together with
BCL2/adenovirus E1B interacting protein 3 (BNIP3) is
essential for the activation of the autophagy-lysosome
pathway. The effect of Akt on mTOR is indirect: Akt
inhibits the tuberous sclerosis complex (TSC) proteins 1
and 2, which act as a GTPase activating protein (GAP) to
inhibit the small G protein Ras homolog enriched in
brain (Rheb) which activates mTOR signaling. mTOR
forms two different protein complexes, the rapamycin-
sensitive mTORC1, when bound to Raptor, and the rapa-
mycin-insensitive mTORC2, when bound to Rictor [5].
TORC2 is required for Akt phosphorylation and acti-
vation [6]. mTORC1 phosphorylates S6 kinase (S6K),
which in turn phosphorylates the ribosomal protein S6
and other factors involved in translation initiation and
elongation, thus stimulating protein synthesis. TORC1
also activates eukaryotic translation initiation factor 4E
(eIF4E) by phosphorylating the inhibitory eIF4E-
binding proteins (4EBPs). Akt also promotes protein
synthesis by phosphorylating and inactivating GSK3b,
thus releasing the GSK3b-dependent inhibition of the
eukariotic translation initiation factor 2B (eIF2B)
(Figure 2).
The activity of the IGF1-Akt pathway is controlled by
several feedback loops (Figure 1). Negative feedback
involves S6K, which inhibits IRS by phosphorylation
at multiple sites, thus inducing its degradation and
altered cell localization [7]. Positive feedback involves
mTORC2, which phosphorylates Akt at serine 473, a
phosphorylation required for maximum activation of
Akt in addition to phosphorylation at threonine 308 by
Figure 1 The insulin-like growth factor 1 (IGF1)-Akt pathway
controls muscle growth via mammalian target of rapamycin
(mTOR) and FoxO. The internal feedback loops that control the
IGF1-Akt pathway are indicated in red. The dotted line indicates that
the effect of Akt on mTOR is indirect, being mediated by the
tuberous sclerosis complex (TSC) proteins 1 and 2 and by Rheb (Ras
homolog enriched in brain). See text for details.
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serine 473 is required for Akt-mediated phosphorylation
of FoxO but not of TSC2, thus it does not affect activa-
tion of S6K [5]. In another feed-forward mechanism,
MAFbx, which is activated by FoxO, acts in turn as
coactivator of FoxO [9]. MAFbx also appears to control
protein synthesis by ubiquitylating and thus promoting
the degradation of the eukariotic translation initiation
factor 3 subunit F (eIF3F), thus suppressing S6K1 activa-
tion by mTOR [10,11]. FoxO factors have been shown
to inhibit mTORC1 and activate Akt by inducing the
expression of sestrin3 and Rictor in cultured mamma-
lian cells [12], but this pathway has not been character-
ized in skeletal muscle in vivo.
The activity of the IGF1-Akt pathway can be modu-
lated by a variety of other factors and pathways acting
on different steps (Figure 3). IGF binding proteins
(IGFBPs), the most important probably being IGFBP5,
can block IGF1 action by inhibiting its binding to the
IGF1 receptor. Mechanical signals via integrin b1a n d
integrin-linked kinase (ILK) lead to phosphorylation of
the IGF1 receptor and activation of the PI3K-Akt path-
way in muscle cells [13]. Whether another downstream
integrin effector, the integrin-dependent focal adhesion
kinase (FAK), affects the IGF1-Akt pathway in skeletal
muscle remains to be established. FAK null mice are
embryonic lethal, and skeletal muscle-specific condi-
tional mutants have not been reported. Overexpression
of FAK by electrotransfer was found to induce slight
hypertrophy in adult rat muscles, but the effect on the
IGF1-Akt pathway was not investigated [14]. Activa-
tion of IRS types is inhibited by phosphorylation of
serine residues induced by inflammatory cytokines
such as tumor necrosis factor a (TNFa)v i aJ u n
N-terminal kinase (JNK) [15]. PTEN (phosphatase and
tensin homolog deleted from chromosome 10) is a
lipid phosphatase that converts PIP3 to PIP2, thus
opposing the action of PI3K, and interfering with Akt
docking to the plasma membrane. Myostatin, also
called growth and differentiation factor 8 (GDF8), acts
as negative regulator of muscle growth, as shown by
the hypertrophic phenotype induced by inactivation of
the myostatin gene [16]. Myostatin, together with acti-
vin A, another member of the TGFb family, acts via its
receptor activin receptor IIB (ActRIIB) on Smad2 and
Smad3, inhibitors of Akt; conversely, mTOR inhibits
Smads [17,18]. In cultured muscle cells, addition of
IGF1 dominantly blocks the effect of myostatin [17]. In
adult skeletal muscle, muscle hypertrophy can be
induced and muscle wasting prevented by blocking
myostatin either via postdevelopmental myostatin gene
knockout, or with follistatin (a myostatin antagonist)
or anti-myostatin antibodies or a soluble ActRIIB
decoy receptor (see [19,20] and references therein).
mTORC1 integrates growth factor signaling with a
variety of signals from nutrients and cellular energy sta-
tus. Direct activation of mTORC1 by amino acids is
mediated by the Rag family of GTPases, which interact
with Raptor [21,22]. By contrast, AMP-activated kinase
Figure 2 The insulin-like growth factor 1 (IGF1)-Akt pathway
controls muscle growth also via glycogen synthase kinase b
(GSK3b). GSK3b inhibits protein synthesis via eukaryotic initiation
factor 2B (eIF2B) and actin filament formation via nebulin and
neuronal Wiscott-Aldrich syndrome protein (N-WASP). See text for
details.
Figure 3 Multiple factors and pathways affect insulin-like
growth factor 1 (IGF1)-Akt signaling. Various factors and
pathways affecting the IGF1-Akt pathway are highlighted in red. See
text for details.
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depletion, inhibits mTORC1 by phosphorylating and
inactivating Raptor [23], and by phosphorylating and
activating TSC2 [24]. The role of AMPK in the control
of muscle fiber size through mTOR inhibition is demon-
strated by the phenotype of AMPKa1 knockout and
AMPKa1/a2 double knockout mice, which develop
muscle hypertrophy [25,26]. mTOR can also be directly
activated independently of PI3K/Akt signaling, by phos-
phatidic acid, generated by phospholipase D (PLD) in
response to mechanical signals induced by eccentric
muscle contractions [27-29].
AMPK can also impinge on the FoxO-dependent pro-
tein degradation pathways. AMPK can activate FoxO
factors by phosphorylation at several regulatory sites dis-
tinct from Akt phosphorylation sites [30]. FoxO-depen-
dent activation of atrogin-1 and muscle atrophy is
inhibited by the peroxisome proliferator activated recep-
tor g coactivator 1a (PGC1a), a transcriptional coactiva-
tor. PGC1a transfection protects adult muscles from
FoxO-dependent atrophy, and the higher levels of
PGC1a in oxidative muscle fibers can explain their
greater resistance to muscle atrophy [31]. Circulating
cytokines, such as TNFa and TNF-related weak inducer
of apoptosis (TWEAK), can activate MuRF1 via the
transcription factor nuclear factor B( N F B) [32,33].
Finally, corticosteroids inhibit the IGF1-Akt pathway by
acting at multiple levels, such as inducing decreased
production of IGF1 and increased production of myosta-
tin [34]. In addition, the glucocorticoid receptor and
FoxO1 synergistically activate the MuRF1 gene [35].
Those listed above most probably represent only a
minor proportion of the interactions of the IGF1-Akt
pathway with other factors and pathways. Indeed, a
recent interactome map based on a yeast two-hybrid
screen for 33 components of the PI3K-mTOR pathway
has identified 802 interactions, including 67 new vali-
dated interactions [36]. An additional complicating fac-
tor is the fact that various components of the IGF1-
Akt pathway exist as multiple isoforms, many of which
are coexpressed in skeletal muscle (Table 1). These
include different splicing variants of IGF1, two types of
IRS (IRS1 and IRS2), different isoforms of both the
regulatory and catalytic subunits of PI3K, two types of
Akt (Akt1 and Akt2) and S6K (S6K1 and S6K2), and
several FoxO factors (FoxO1, FoxO3 and FoxO4). The
different roles of some of these isoforms will be dis-
cussed below.
A large number of transgenic and knockout mouse
models involving components of the IGF1-Akt pathway
have been generated and are listed in Tables 2 and 3,
respectively. In vivo transfection experiments leading to
Table 1 Isoforms of major components of the IGF1-Akt pathway
Component Isoforms References
IGF1
1 Two (mouse: 1A, 1B) or three (human: 1A, 1B & 1C) isoforms, differing in the C terminal peptide (E peptide); another
two (mouse: 2A, 2B) or three (human: 2A, 2B & 2C) isoforms differing in signal peptide because of utilization of exon 2
instead of exon 1
[49]
IGF1 receptor Heterotetramer made of two a-subunit (IGF-binding) and two b-subunit (tyrosine kinase). No isoforms, but hybrids
with insulin receptor are present in skeletal muscle
[112]
IRS
2 IRS1 and IRS2 [65,113]
PDK1
3 No isoforms [114]
PI3K
4 (class I) Heterodimer of p85 regulatory and p110 catalytic subunits. p85: three isoforms (p85a, p55a, p50a) encoded by a
single gene; two other isoforms (p85b, p55g) coded by other genes. p55g is not expressed in muscle. p110: three
isoforms (p110a, p110b, p110δ). p110δ is not expressed in muscle
[115]
Akt/PKB
5 Akt1/PKBa, Akt2/PKBb & Akt3/PKBg. Akt3 is not expressed in muscle [4,116]
mTOR
6 No isoforms, but mTOR can interact with different partners: Raptor in the rapamycin-sensitive complex mTORC1, or
Rictor in the rapamycin-insensitive complex mTORC2
[5]
S6K
7 S6K1 and S6K2 [117-119]
4EBP
8 4EBP1, 4EBP2, 4EBP3. 4EBP3 is not expressed in muscle [120]
FoxO 4 isoforms: FoxO1, FoxO3, FoxO4 and FoxO6. FoxO6 is not expressed in muscle [121]
1Insulin-like growth factor.
2Insulin receptor substrate.
33-Phosphoinositide-dependent kinase 1, coded by the PDPK1 gene (unfortunately the same abbreviation PDK1 is also used to indicate the pyruvate
dehydrogenase kinase isoform 1, coded by the PDK1 gene).
4Phosphoinositide-3 kinase.
5Protein kinase B.
6Mammalian target of rapamycin.
7S6 kinase.
8Eukaryotic initiation factor 4E binding protein.
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tal muscle are listed in Table 4.
IGF1 and IGF1 receptor
IGF1 was initially considered purely as a circulating
growth factor produced by the liver and mediating the
effect of growth hormone on body growth. However, sub-
sequent studies showed that IGF1 is also expressed
locally in many tissues, including skeletal muscle, sug-
gesting that autocrine/paracrine effects of local IGF1 may
be a major mechanism controlling tissue growth. Igf1
null mice exhibit severe growth retardation and most die
soon after birth [37-39], whereas targeted ablation
experiments showed that liver-derived IGF1, although it
is the principal source of IGF1 in the serum, is not
required for postnatal body growth [40,41]. However, this
interpretation was challenged by the demonstration that
conditional expression of IGF1 in the liver of an Igf1 null
background contributes to about 30% of the adult body
size [42]. This discrepancy was explained by the fact that
a residual fraction of circulating IGF1 is detected in the
liver-specific knockout [40,41] because of incomplete Igf1
gene excision [43]. In a similar study, elevated serum
concentrations of IGF1, induced by overexpressing a rat
Igf1 transgene specifically in the liver of Igf1 null mice,
were able to rescue the severe growth-retarded pheno-
type observed in these mice [44]. To define the effects of
IGF1 produced by muscle cells, a transgenic construct
was generated in which expression of a human IGF1
cDNA was driven by the avian skeletal a-actin gene [45].
IGF1 concentration in the serum was similar in wild-type
and transgenic mice, but transgenic mice developed ske-
letal muscle hypertrophy [45-47]. In these mice, IGF1
overexpression was not sufficient to prevent the decrease
in muscle mass induced by hind-limb unloading [46].
However, glucocorticoid-induced muscle atrophy was
prevented by IGF1 overexpression via electroporation in
adult rats [48].
The Igf1 gene can produce multiple transcripts by
alternative RNA processing, thus generating divergent
peptides at the carboxyl terminus, called the E pep-
tides. Two isoforms, IGF1A and IGF1B, are found in
most mammals, and an additional form, IGF1C, is pre-
sent in primates and humans [49]. The E peptides
appear to be essential for muscle growth regulation
because viral delivery of IGF1A or IGF1B promoted
functional hypertrophy in mouse muscles, whereas
delivery of mature IGF1 devoid of E peptide failed to
cause an increase in muscle mass [50]. The effect of an
IGF1 isoform (IGF1A) was investigated in a transgenic
mouse model, in which expression of this isoform was
driven by the myosin light chain 1 fast promoter [51].
The transgenic mice showed postnatal increase in
muscle mass and strength, and were protected from
age-related muscle atrophy and weakness. Moreover,
aging transgenic muscles retained a regenerative capa-
city comparable with that of young animals. Surpris-
ingly, Akt activation was not detected in these mice
[52], suggesting that IGF1 may signal via alternative
pathways. A potential alternative pathway could be the
serum- and glucocorticoid-responsive kinase 1 (SGK1),
a PI3K-dependent kinase with structural homology to
Akt, which is strongly expressed in many tissues,
including skeletal muscle and heart [53]. SGK1 is acti-
vated by IGF1, PI3K and PDK1, and can induce phos-
phorylation of S6K and GSK3b in cardiomyocytes [54]
and phosphorylation of FoxO3 in various cell types
[55]. However, this alternative pathway has not been
explored in skeletal muscle. IGF1-dependent signaling
via the mitogen-activated protein kinase/extracellular
signal-regulated receptor kinase (MAPK/ERK) pathway
has also been implicated in IGF1-dependent muscle
growth regulation [56,57], however a constitutively
active Ras double mutant that selectively activates the
ERK pathway did not induce hypertrophy of regenerat-
ing muscle fibers [58].
Table 2 Transgenic models of the IGF1-Akt pathway: effect on growth
Genotype
1 Viability Phenotype References
ASA-hIGF1 Viable Muscle hypertrophy [45,47]
MLC1-IGF1 Viable Muscle hypertrophy [51]
MCK-d.n. IGF1 receptor
2 Viable Transient delay of postnatal muscle growth; unaffected
overload-induced muscle hypertrophy; impaired muscle regeneration
[59-62]
HSA-Akt1, inducible Viable Muscle hypertrophy [79]
MCK-myrAkt1, inducible Viable Muscle hypertrophy [80]
MLC1f-myrAkt1, inducible Viable Muscle hypertrophy [82]
HSA-FoxO1 Viable Muscle atrophy [90]
1Promoters used to drive transgene expression: ASA = avian skeletal actin; HSA = human skeletal actin; MCK = muscle creatine kinase; MLC1 = myosin light chain
1 fast.
2This transgene acts as a dominant negative for both the insulin-like growth factor 1 receptor and the insulin receptor, thus causing diabetes.
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Genotype
1 Viability Growth phenotype References
Igf1 null Severe neonatal
lethality
Severe growth retardation [37-39]
Igf1 null in muscle (Mef2c-Cre) Viable Normal growth [63]
Igf1 receptor null Severe neonatal
lethality
Severe growth retardation [37,39]
Igf1 receptor null in muscle (Mef2c-
Cre)
Viable Reduced body weight, reduced muscle fiber number and size [63]
IRS1 null Viable Reduced growth (weight 30-60% of control) [64,122]
IRS2 null Viable Almost normal growth (birth weight 90% of control) [65]
PI3K p85a + p55a + p50a null Perinatal lethality [66]
PI3K p85a + p55a + p50a null in
heart & muscle (MCK-Cre)
Viable Normal growth [68]
PI3K p85b null Viable Normal growth [67]
PI3K p85a + p55a + p50a null in
heart & muscle (MCK-Cre) and p85b
null
Viable Reduced heart size but not muscle size [68]
PTEN null in heart & muscle (MCK-Cre) Viable Cardiac hypertrophy but normal skeletal muscle growth; unaffected
overload-induced muscle hypertrophy; improved muscle regeneration
[70,71,123]
PDK1 null Embryonic lethality [124]
PDK1 knock-in mutant unable to bind
phosphoinositides
Viable Reduced growth (weight 35% of control) [125]
PDK1 null in heart & muscle (MCK-Cre) Lethal at 5-11 weeks Dilated cardiomyopathy but no change in muscle [73]
Akt1 null Viable but shorter life
span
Mild growth retardation (weight 80% of control) [74,75]
Akt2 null Viable Normal growth [76]
Akt1+Akt2 null Neonatal lethality Severe growth retardation (birth weight 50% of control), marked
muscle atrophy
[77]
TSC1 null Embryonic lethality [126]
TSC2 null Embryonic lethality [127]
mTOR null Embryonic lethality [128,129]
mTOR null in muscle (HSA-Cre) Viable but premature
death
Reduced postnatal growth due to reduced fast muscle growth, severe
myopathy
[88]
Raptor null Embryonic lethality [6]
Raptor null in muscle (HSA-Cre) Viable Normal growth [87]
Rictor null in muscle (HSA-Cre) Viable Reduced postnatal growth with severe myopathy and premature death [87]
S6K1 null Viable Reduced growth (birth weight 80% of control), reduced muscle growth
(fiber size 80% of control in adult mice)
[89,117]
S6K2 null Viable Normal growth [130]
S6K1+S6K2 null Perinatal lethality Reduced growth [130]
4EBP1+4EBP2 null Viable Normal growth [131]
FoxO1 null Embryonic lethality [132,133]
FoxO1 null in muscle (HSA-Cre) Viable Normal growth, slow to fast switch in muscle [134,135]
FoxO3 null Viable but female
sterility
Normal growth [133,36]
FoxO4 null Viable Normal growth [137]
FoxO3+FoxO4 null Viable Normal growth [137]
MAFbx null Viable Reduced muscle atrophy after denervation [92]
Murf1 null Viable Reduced muscle atrophy after denervation [92]
1 Promoters used to drive Cre recombinase expression: HSA = human skeletal actin; MCK = muscle creatine kinase; Mef2c = a promoter that lies 71 kb upstream
of the first translated exon of the Mef2c gene and is sufficient to direct expression exclusively to skeletal muscle from embryonic day 8.5.
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for IGF1 and IGF1 receptor was a dominant-negative,
kinase-inactive form of the b-subunit of IGF1 receptor
driven by a muscle-specific promoter (MKR mice) [59].
Formation of a hybrid of the mutated IGF1 receptor with
the endogenous IGF1 and insulin receptors caused
impaired insulin and IGF1 receptor signaling pathways,
specifically in skeletal muscle. The main phenotype of
these mice was the development of peripheral insulin
resistance and type 2 diabetes [59]. Muscle growth was
transiently delayed from birth to 3 weeks of age, but
muscle mass and force was normal in the adult [60].
Compensatory hypertrophy of the plantaris muscle after
ablation of the synergistic gastrocnemius muscle, and
associated Akt and S6K activation, were unaffected in
these mice [61], but muscle regeneration was impaired
[62]. More recently, specific loss-of-function mouse mod-
els have been generated. Muscle-specific knockout of the
Igf1 receptor gene caused impaired skeletal muscle devel-
opment with reduction in myofiber number and area and
reduced numbers of type 1 fibers in gastrocnemius mus-
cle [63]. By contrast, mice lacking Igf1 had no obvious
phenotype, and their body weights were indistinguishable
from control littermates at all postnatal times (reported
as ‘data not shown’ in [63]).
IRS, PI3K and PDK1
IRS1 null mice have much reduced growth (30-60% of
control) [39,64], whereas IRS2 null mice have almost
normal growth (about 90% of control), but develop type
2 diabetes [65], therefore IRS1 is thought to be down-
stream of the IGF1 receptor, and IRS2 downstream of
the insulin receptor (Table 3). However, muscle-specific
inactivation of the IRS genes has not yet been reported.
PI3K p85a null mice have perinatal lethality, apparently
due to liver necrosis [66], whereas PI3K p85b null mice
are viable and have normal growth [67]. Conditional
deletion of the p85a gene in skeletal muscle and heart
showed normal growth [68], but when these mice were
crossed with p85b null mice, the resulting double-
mutant animals showed reduced heart but not reduced
skeletal muscle size [68]. By contrast, constitutively
active PI3K was found to induce muscle hypertrophy
when transfected into regenerating skeletal muscle
[69]. Conditional deletion of the PTEN gene in skeletal
muscle and heart leads to hypertrophy of cardiac but
not skeletal muscle. Overload-induced skeletal muscle
hypertrophy is also unaffected by PTEN knockout [70],
but maturation of regenerating muscle fibers is accel-
erated [71]. A skeletal muscle- and cardiac-enriched
microRNA, miR-486, has been shown to target and
inhibit the PI3K inhibitor PTEN, thus activating the
Akt pathway [72]. Expression of miR-486 is regulated
by myocardin-related transcription factor A (MRTF-A)
and serum response factor (SRF). However, a role of
miR-486 on muscle growth regulation has not yet been
documented by in vivo genetic approaches. Conditional
deletion of PDK1 in heart and muscle leads to dilated
cardiomyopathy but no apparent change in muscle
[73]. Thus, genetic evidence, based on loss-of-function
Table 4 In vivo transfection experiments leading to perturbation of the IGF1-Akt pathway in adult skeletal muscle
1
Transgene Perturbation Effect References
Igf1 (via virus) Overexpression of Igf1 Muscle fiber hypertrophy (and muscle regeneration) [50,106]
Igf1 Overexpression of Igf1 Prevention of glucocorticoid-induced muscle atrophy [48,138]
RasV12C40 (Ras double mutant) Activation of the PI3K-Akt pathway Muscle fiber hypertrophy, which is blocked by
rapamycin
[58,69]
c.a. PI3K
2 Activation of PI3K Muscle fiber hypertrophy [69,78]
c.a. Akt Activation of Akt Muscle fiber hypertrophy, which is blocked by
rapamycin
[69,78]
c.a. Akt (via virus) Activation of Akt Muscle fiber hypertrophy [139]
c.a.FoxO3 Activation of FoxO3 Muscle fiber atrophy and activation of atrogin-1
reporter
[91]
Small interfering RNA to FoxO1
and FoxO3
Knockdown of FoxO1 and FoxO3 by RNA
interference
Prevention of atrogin-1 reporter upregulation induced
by starvation
[91]
Rheb
3 Activation of Rheb and mTORC1 Muscle fiber hypertrophy [140]
Small interfering RNA to N-WASP Knockdown of N-WASP
4 by RNA
interference
Muscle fiber atrophy [86]
1Experiments based on intramuscular injection of plasmid DNA or viral vector or small interfering RNA expression vector. Injection of plasmid DNA or siRNA
expression vector was followed by electroporation.
2Constitutively active PI3K.
3Ras homolog enriched in brain.
4Neuronal Wiscott-Aldrich syndrome protein (N-WASP).
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skeletal muscle growth is still missing.
Akt/PKB
Disruption of the Akt1 gene causes growth retardation
and apoptosis [74,75], whereas deletion of Akt2 causes
defects in glucose metabolism but not altered growth
[76]. When both Akt1 and Akt2 genes were deleted,
skeletal muscle atrophy at embryonic day 18.5 was
observed, together with dwarfism, impaired skin and
bone development, and reduced adipogenesis [77]. The
striking effect of Akt1 on muscle size was demonstrated
by in vivo transient transfection of a constitutively active
Akt1 [69,78] (Figure 4A), andb yt r a n s g e n i cm i c eo v e r -
expressing a constitutively active inducible Akt1 trans-
gene in skeletal muscles [79-82]. Muscle hypertrophy
was rapidly achieved in all cases when Akt1 expression
was induced in the adult animal for a period ranging
from 1 to 3 weeks. Downstream mediators of protein
synthesis (S6K, S6) were activated, but no incorporation
of satellite cells was observed [82]. Akt1 hypertrophic
muscles showed increased strength, demonstrating that
a functional hypertrophy was induced [80,82]. Moreover,
muscle mass was completely preserved in denervated
transgenic Akt mice [18]. Akt activation causes multiple
changes in muscle gene expression, documented by
microarray analyses [80,82,83]. The effects of Akt on
muscle mass regulation can be mediated by several
different downstream effectors, including GSK3b,
mTOR and FoxO.
GSK3b
A dominant-negative form of GSK3b has been shown to
induce hypertrophy in skeletal myotubes [84], and over-
expression of wild-type GSK3b in the heart induces a
30% decrease in heart size [85]. However, in vivo studies
with GSK3b mutants in skeletal muscle have not been
reported. A novel mechanism mediating the effect of
GSK3b on muscle growth has been described recently
[86]. GSK3b is able to phosphorylate nebulin at two Ser
sites in the C-terminal region of nebulin localized to
the Z-disk, thus preventing the interaction of nebulin
with neuronal Wiscott-Aldrich syndrome protein (N-
WASP), a ubiquitously expressed member of the WASP
family, which is involved in actin assembly (Figure 2).
IGF1-Akt signaling, by inhibiting GSK3b, allows the
interaction of N-WASP with the unphosphorylated
nebulin; the consequent recruitment of N-WASP to the
Z-disk promotes actin nucleation and elongation of
actin filaments. This process appears to be relevant to
muscle growth in vivo, because long-term knockdown
of N-WASP in adult mouse muscles causes atrophy of
the transfected muscle fibers [86]. It was therefore sug-
gested that IGF1-Akt signaling controls myofibril
growth and maintenance via the GSK3b-nebulin-N-
WASP pathway.
Figure 4 Myofiber hypertrophy or atrophy induced by transfection of skeletal muscle with mutants of Akt or FoxO. (A) Regenerating
rat soleus muscle transfected with plasmid coding for constitutively active Akt1 linked to a hemagglutinin (HA) epitope. Muscle examined
7 days after transfection; section stained for the HA tag. Note the striking hypertrophy of labeled myofibers compared with untransfected
neighbouring fibers. Modified from [69]. (B,C) Adult mouse tibialis anterior muscle transfected by electroporation with plasmid coding for
constitutively active Ha-tagged FoxO3. Muscle examined 14 days after transfection; section stained for the HA tag. Note the striking atrophy of
labeled myofibers compared with untransfected neighboring fibers. A phase-contrast image of the same field is shown in the right panel.
Modified from [91].
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mTOR is part of two multiprotein complexes, TORC1,
which contains contains Raptor and TORC2, which con-
tains Rictor. To define the role of mTOR complexes in
skeletal muscle, mice with muscle-specific ablation of
Raptor and Rictor were generated [87]. Muscles from
Rictor knockout mice were indistinguishable from wild-
type controls. By contrast, Raptor-deficient muscles
became progressively dystrophic, and were impaired in
their oxidative capacity [87]. These changes were
accompanied by decreased muscle force and downregu-
lation of genes involved in mitochondrial biogenesis,
including PGC-1a. A similar, although not identical,
phenotype was observed in muscle-specific mTOR-
deficient mice [88]. Like Raptor knockouts, mTOR-
deficient muscles develop a myopathy reminiscent of
muscular dystrophy, together with impaired oxidative
metabolism. The myopathy was more severe in mTOR
knockout than in Raptor knockout mice, possibly due to
reduction in the content of dystrophin and other com-
ponents of the dystrophin-glycoprotein complex. It was
suggested that mTOR directly controls dystrophin
transcription in a rapamycin- and kinase-independent
manner [88].
Raptor and Rictor have different susceptibilities to rapa-
mycin treatment, with Raptor activity being blocked by
rapamycin, whereas Rictor activity is not. Nevertheless,
Raptor inhibition and rapamycin treatment do not cause
the same effect on muscles. Rapamycin blocks muscle
growth in regenerating or Akt transfected muscles [69,78]
but does not cause atrophy or dystrophy in adult mice
treated for 15 days [18]. mTOR controls protein synthesis
via different targets, including S6K, which exists in
two isoforms, S6K1 and S6K2. S6K1 and S6K2 double-
knockout mice have reduced muscle fiber size with
unchanged number of myonuclei [89]. Deletion of S6K1
is sufficient to reproduce this atrophic phenotype.
FoxO
The transcription factors of the FoxO family have
emerged as major regulators of the muscle atrophy pro-
gram. Mice overexpressing FoxO1 under a muscle-
specific promoter have muscle atrophy and increased
levels of the lysosomal protease cathepsin L [90]. FoxO3
is induced during muscle atrophy, and its overexpres-
sion is able to reduce muscle mass in vivo:t h es t r i k i n g
effect of a constitutively active mutant of FoxO3 when
transfected into skeletal muscle is illustrated in Figure 4
(B,C). By contrast, expression of dominant-negative
FoxO3 inhibits dexametasone-induced muscle atrophy
[91]. FoxO3 acts on the two major pathways of muscle
protein degradation, the proteasomal and the autopha-
gic-lysosomal pathways.
Direct evidence for FoxO-dependent activation of the
ubiquitin-proteasome pathway was obtained with the
demonstration that the muscle-specific ubiquitin ligases
atrogin-1/MAFbx and MuRF1, which are induced in var-
ious models of muscle atrophy [92,93], are transcriptional
targets of FoxO factors, and are upregulated by FoxO3
transfection in adult muscle [91,94]. Their role in mus-
cle-mass regulation is supported by the finding that mus-
cle atrophy induced by denervation is partially prevented
in both MuRF1 null and atrogin1/MAFbx null mice [92].
M u R F 1i si n v o l v e di nt h ed e g r a d a t i o no fm y o s i nh e a v y
chains and other thick filament proteins, such as myosin
light chains and myosin-binding protein C [95,96].
MuRF1 belongs to the muscle-specific RING finger pro-
tein family, which also includes MuRF2 and MuRF3.
A redundant function of the different MuRFs is sug-
gested by the finding that mice lacking a single MuRF
gene do not have a striking skeletal muscle phenotype
[92,97,98]. By contrast, MuRF1 and 3 double-knockout
mice develop skeletal and cardiac muscle myopathy with
myosin accumulation [99], and MuRF1 and 2 double-
knockout mice have mild skeletal muscle hypertrophy
and have reduced muscle loss during aging [100].
The role of FoxO3 as an inducer of autophagy is sup-
ported by the finding that transfection of adult muscle
fibers with constitutively active FoxO3 causes accumula-
tion of autophagic vacuoles, whereas fasting-induced
autophagy is blocked by dominant-negative FoxO3 and
by RNA interference-mediated FoxO3 knockdown
[81,101]. FoxO3 is required for the upregulation of
autophagy-related genes, such a LC3 and Bnip3 [81].
Inhibition of autophagy by muscle-specific knockout of
the autophagy gene Atg7 was found to cause muscle
atrophy, accompanied by a decrease in muscle force
with accumulation of altered mitochondria and aberrant
concentric membranous structures [102]. Moreover,
inhibition of autophagy exacerbated muscle loss during
denervation and fasting, suggesting that the persistence
of dysfunctional organelles affects the progression of
muscle atrophy [102]. The normal operation of the
autophagic machinery is thus required for the disposal
of altered cell organelles and the maintenance of muscle
fiber integrity. An unexpected result was the finding
that mTOR, which is considered as a major regulator of
autophagy in different cell systems, does not appear to
play a major role in muscle autophagy, as treatment
with the mTOR inhibitor rapamycin has a limited effect
on autophagy in skeletal muscle both in vitro and
in vivo [81,101].
Open questions
S e v e r a lo p e nq u e s t i o n so nt h er o l eo ft h eI G F 1 - A k t
pathway in skeletal muscle remain to be answered,
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IGF1 and the FoxO isoforms. Two general points that
need to be addressed in future studies will be briefly
considered here.
The role of the IGF1-Akt pathway in adult skeletal muscle
There is no doubt that IGF1 is a major regulator of mus-
cle mass during development, thanks to its effect on myo-
genic cell proliferation and differentiation [103]. As to the
role of IGF1 in adult skeletal muscle, several studies indi-
cate that IGF1 can induce hypertrophy and block atrophy.
In adult rats, local infusion of recombinant IGF1 results
in muscle hypertrophy [104,105] and plasmid-mediated
IGF1 gene transfer prevents corticosteroid-induced mus-
cle atrophy [48]. In adult mice, virus-mediated IGF1 gene
transfer results in muscle hypertrophy and prevents
aging-dependent loss in muscle mass and force [50,106].
However, it is not clear whether IGF1 is involved in med-
iating the effect of load on adult muscle mass. Overex-
pression of IGF1 in the skeletal muscle of transgenic mice
did not prevent unloading-induced muscle atrophy [46],
although IGF1 transgene expression was decreased by
unloading in these experiments. Overload hypertrophy
was also unchanged in transgenic mice overexpressing a
dominant-negative form of the IGF1 receptor [61],
although interpretation of this model is complicated by
the double effect of the transgene on both insulin and
IGF1 signaling. The pathways mediating the effect of
unloading and overloading on muscle size have not been
identified, and as discussed above, it is possible that the
Akt-mTOR pathway is involved either via integrin-ILK or
via a direct effect on mTOR.
The role of IGF1 and its downstream effectors in adult
skeletal muscle cannot be determined using traditional
transgenic and knockout approaches, because developing
muscles have greater plasticity than adult muscles, thus
compensatory adaptations might occur in response to
gene overexpression or ablation that are not seen when
the genetic perturbation is induced in adult animals.
This might account for the lack of a muscle phenotype
in certain knockout models, for example, in the PI3K
and PDK1 knockouts. Other knockout models cause
maladaptative changes leading to muscle dystrophy
rather than atrophy, such as that seen in the mTOR and
Raptor knockout models. An understanding of the effect
of genetic perturbation in adult rather than developing
muscle is especially important for the identification of
therapeutic targets and the design of countermeasures
to prevent muscle wasting. To obtain useful information
in this respect, it is essential to use inducible transgenic
approaches, in which transgene overexpression or gene
knockout is induced in adult animals. However, to
our knowledge, the Akt inducible model is the only
inducible model developed to date for the study of the
IGF1-Akt pathway. Alternatively, in vivo transfection
procedures can be used to explore the effect of trans-
gene overexpression or gene knockdown by RNAi in
adult muscles.
The effect of IGF1-Akt pathway activation on satellite cells
Muscle growth and muscle regeneration require the par-
ticipation of satellite cells, and other cell types, including
cells of blood vessels and, in the case of regeneration,
inflammatory cells. This aspect must be considered in
genetic models involving overproduction of IGF1, as this
growth factor is known to act on different cell types,
because of the presence of the IGF1 receptor in satellite
cells and non-muscle cells. The effect on satellite cells is
especially important for muscle hypertrophy. Satellite
cells were reported to play a crucial role in the hyper-
trophic response induced by viral-mediated gene trans-
fer of IGF1 in adult mouse muscles, as shown by the
fact that gamma-irradiation, used to block satellite-cell
proliferation, was found to reduce the hypertrophic
effect of IGF1 overexpression [107]. However, interpre-
tation of this experiment is complicated by the possibi-
lity that the reduced hypertrophic response may be due
to effects of irradiation on myofiber protein synthesis
[108], and perhaps on protein degradation as well. In
another study on IGF1 transgenic mice, the finding that
IGF1 overexpression causes first an increase in DNA, and
only several weeks after birth an increase in protein
mass, was interpreted as reflecting a primary effect on
satellite-cell proliferation and fusion during the early
postnatal stages, when satellite cells undergo active prolif-
eration [47]. This interpretation would be consistent with
the view that a growth stimulus is required for IGF1 to
induce muscle hypertrophy in vivo [109]. However, satel-
lite-cell proliferation was not directly examined in these
studies. Satellite-cell proliferation and fusion leading to
increase in myonuclei occurs during postnatal muscle
growth [110] and during compensatory hypertrophy
induced by ablation of synergistic muscles [111], as
demonstrated by electron microscope autoradiographs
after
3H-thymidine labeling. However, using an inducible
transgenic model of muscle hypertrophy, no significant
BrdU incorporation could be detected in satellite cells
after short-term Akt activation in adult skeletal muscle,
yet muscle hypertrophy was accompanied by increased
force generation [82]. Thus, satellite-cell proliferation and
fusion is not a prerequisite for a functional hypertrophy
induced by Akt activation in adult skeletal muscle.
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